SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Texas Biotech (TXB)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: NVestor who wrote (94)3/4/1997 11:08:00 AM
From: Dauntless   of 834
 
You may be missing one or two things,

1- using novastan does not necessarily eliminate the need for monitoring the patient's coagulation.

2- I think the drug will be priced higher than $20 per patient.

Also, don't forget the other application for this drug. Results of the trial of novastan in conjunction with TPA/Streptokinase on acute MI patients will be presented this month at Cardiology Meeting. Chance for another huge market.

This is a good thread - keep it going
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News